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Background: MiR-17-92 cluster and its paralogues have emerged as crucial regulators of many oncogenes and
tumor suppressors. Transforming growth factor-β receptor II (TGFβR2), as an important tumor suppressor, is involved
in various cancer types. However, it is in cancer that only two miRNAs of this cluster and its paralogues have been
reported so far to regulate TGFβR2. MiR-93 is oncogenic, but its targetome in cancer has not been fully defined.
The role of miR-93 in nasopharyngeal carcinoma (NPC) still remains largely unknown.
Methods: We firstly evaluated the clinical signature of TGFβR2 down-regulation in clinical samples, and next used a
miRNA expression profiling analysis followed by multi-validations, including Luciferase reporter assay, to identify
miRNAs targeting TGFβR2 in NPC. In vitro and in vivo studies were performed to further investigate the effects of
miRNA-mediated TGFβR2 down-regulation on NPC aggressiveness. Finally, mechanism studies were conducted to
explore the associated pathway and genes influenced by this miRNA-mediated TGFβR2 down-regulation.
Results: TGFβR2 was down-regulated in more than 50% of NPC patients. It is an unfavorable prognosis factor
contributing to clinical NPC aggressiveness. A cluster set of 4 TGFβR2-associated miRNAs was identified; they are all
from miR-17-92 cluster and its paralogues, of which miR-93 was one of the most significant miRNAs, directly
targeting TGFβR2, promoting cell proliferation, invasion and metastasis in vitro and in vivo. Moreover, miR-93 resulted in
the attenuation of Smad-dependent TGF-β signaling and the activation of PI3K/Akt pathway by suppressing TGFβR2,
further promoting NPC cell uncontrolled growth, invasion, metastasis and EMT-like process. Impressively, the knockdown
of TGFβR2 by siRNA displayed a consentaneous phenocopy with the effect of miR-93 in NPC cells, supporting TGFβR2
is a major target of miR-93. Our findings were also substantiated by investigation of the clinical signatures of miR-93
and TGFβR2 in NPC.
Conclusion: The present study reports an involvement of miR-93-mediated TGFβR2 down-regulation in NPC
aggressiveness, thus giving extended insights into molecular mechanisms underlying cancer aggressiveness.
Approaches aimed at blocking miR-93 may serve as a promising therapeutic strategy for treating NPC patients.
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Transforming growth factor-β (TGF-β) signaling has
tumor suppressive and pro-oncogenic functions in ac-
cordance with tumor stage [1]. Its abrogation is always
accomplished by either blockade of TGF-β responses or
the acquisition of genetic alterations and epigenetic modi-
fications in its components including transforming growth
factor-β receptor II (TGFβR2) [2]. TGFβR2, as a tumor-
suppressor gene [3,4] is downregulated in multiple cancer
types including head and neck squamous cell carcinoma
(HNSCC) and is generally related to cancer aggressive
behavior [5-9]. Cancer cells always lose their sensitivity
to TGF-β-mediated growth inhibitory responses upon
TGFβR2 down-regulation [10]. The mechanisms under-
lying the downregulation of TGFβR2 expression in can-
cer cells have been investigated, showing that repressed
expression of TGFβR2 in microsatellite instability-high
colorectal cancer and esophageal adenocarcinoma in-
volves hypermethylation of the TGFβR2 promoter re-
gion [11,12]. However, TGFβR2 promoter methylation
is not frequent in some cancers such as Head and neck
squamous cell carcinoma (HNSCC) (11.4%) [13], al-
though there is a frequent loss of TGFβR2, suggesting
that other mechanisms may contribute to the downreg-
ulation of TGFβR2 expression.
MiRNAs have emerged as important regulators of gene
expression. They can modulate multiple biological pro-
cesses by inducing translational inhibition and/or mRNA
degradation of protein-coding genes. The miR-17-92 clus-
ter is among the best-studied miRNA clusters in carcino-
genesis, also known as ‘oncomiR-1’ [14]. It has pivotal roles
in a variety of cancers such as colorectal cancer [15-17],
breast cancer [18-21], pancreatic cancer [22,23], ovarian
cancer [24], lung cancer [25,26], and hepatocellular carcin-
oma [27-29]. MiR-93, derived from a paralogue (miR-106b-
25) of miR-17-92 cluster, is up-regulated in various types of
cancers [30-32]. The identified targets of miR-93 include
LATS2 [33], AICDA [34], ITGB8 [35], PTEN [36], VEGFA
[37], TP53INP1 [38], DAB2 [39], etc., suggesting that miR-
93 may play oncogenic roles through diverse mechanisms.
However, the targetome of miR-93 in cancer has not been
fully defined so far. The role of miR-93 in nasopharyngeal
carcinoma (NPC) still remains largely unknown.
We previously found a reduced TGFβR2 expression in
NPC [40], which was subsequently supported by the
findings from Zhang et al. [41]. Although many miRNAs
(For example miR-26a [42,43], miRNA-18a [44], miR-
18b [45], miR-218 [46], miR-216b [47], miR-663 [48],
miR-155 [49], miR-205 [50], EBV-encoded miRNAs [51],
etc.) have been reported to be involved in NPC carcino-
genesis, no evidence was given for their associations
with TGFβR2 down-regulation.
In the current study, using a miRNA expression pro-
filing analysis in NPC samples stratified by TGFβR2expression level, we identified a cluster set of 4 TGFβR2-
associated miRNAs (miR-93, miR-20a, miR-20b, and miR-
18a). They are all from miR-17-92 cluster and its paralogues,
of which miR-93 was one of the most significant miRNAs.
We demonstrated that miR-93 could directly suppress
TGFβR2 and facilitate NPC aggressiveness (NPC cell
growth, metastasis and EMT-like process). Mechanistic
investigation disclosed that miR-93 could result in attenu-
ated Smad-dependent TGF-B pathway and activated
PI3K/Akt pathway by suppressing TGFβR2.
Thus, our study first reports a miR-93-mediated
TGFβR2 down-regulation in NPC, extending novel
mechanistic insights into the role of miR-93 in cancer
aggressiveness. Blocking of miR-93 may be a promise
for cancer therapy.
Results
TGFβR2 down-regulation is associated with NPC
aggressiveness
Our previous study reported a down-regulated TGFβR2
expression in NPC [40], so we initially confirmed it in
the present study. TGFβR2 expression was indeed ob-
served to be significantly reduced in NPC patients rela-
tive to non-cancerous nasopharyngeal (NP) (Figure 1A).
Next, we investigated the clinical signature of TGFβR2
down- regulation using IHC in additional 300 clinical
NPC samples. TGFβR2 protein was down-regulated in
51.9% (108/208) of NPC, 38.5% (5/13) of atypical hyper-
plasia, 9.1% (2/22) of normal squamous epithelium, and
5.3% (3/57) of normal epithelium, displaying a gradual
reduction trend from normal epithelium to NPC (Table 1).
Pathological analysis showed that the expression level of
TGFβR2 is negatively correlated with T classification (the
size of the primary tumor and whether it has invaded
nearby tissue), N classification (the degree of spread to re-
gional lymph nodes), and clinical stage of NPC patients
(Additional file 1: Table S1). Kaplan-Meier survival ana-
lysis revealed that TGFβR2 expression was significantly
correlated with patient overall survival (Figure 1B, C and
Additional file 2: Figure S1). Multivariate survival analysis
using the Cox's proportional hazards model showed a
close correlation of low TGFβR2 protein expression with
clinical prognosis (Additional file 1: Table S2).
Subsequently, we examined the TGFβR2 expressions
in 4 NPC cell lines (CNE1, CNE2, 5-8 F, 6-10B), pooled
NPC tissues, and an immortalized primary nasopharyn-
geal epithelial cell line (NP69). The mRNA and protein
expressions of TGFβR2 were generally down-expressed
in NPC cells and NPC tissues relative to NP69. The
more metastatic or aggressive NPC cells (such as CNE-
2 and 5-8 F) had relatively lower TGFβR2 expression
than that of NPC cells (such as CNE1 and 6-10B) with
less metastatic or aggressive potential (Additional file 2:
Figure S2).
Figure 1 TGFβR2 down-regulation is associated with NPC aggressiveness. (A) TGFβR2 mRNA expression was detected by qRT-PCR in 21 NP
tissues and 35 NPC tissues. Values represent mean ± SD, ***P < 0.001. (B) Representative TGFβR2 IHC images (400×). a. Normal nasopharynx
epithelium, b. NPC with high TGFβR2 expression, c. NPC with low TGFβR2 expression. (C) Kaplan-Meier survival analysis in NPC patients according
to TGFβR2 protein expression levels. The log-rank test was used to calculate p values (p < 0.001).
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TGFβR2 down-regulation to NPC aggressiveness.
MiR-93 suppresses TGFβR2 in NPC
To investigate if miRNAs are involved in regulation of
TGFβR2 expression in NPC, we first selected 22 clinical
samples and stratified them into 3 groups based on the
mRNA level of TGFβR2: (1) high expression NP group
(H-NP) containing 8 NP samples, (2) high expression NPC
group (H-NPC) containing 7 NPC samples, and (3) low
expression NPC group (L-NPC) containing 7 NPC sam-
ples (Additional file 2: Figure S3). We then conducted a
miRNA expression profiling analysis for these 3 groups.
As shown in Figure 2A and Additional file 1: Table S3, sig-
nificantly higher expressions of miR-93, miR-20a, miR-Table 1 A gradual reduction trend of TGFβR2 protein express
Group Protein expression (n)
Total Low High S/N/A/C
S 22 2 20 <0.001*
N 57 3 54
A 13 5 8
C 208 108 100
S: Squamous epithelium; N: Normal epithelium; A: Atypical hyperplasia; C: NPC.
n: Number of cases. *Kruskal Wallis Test; #Chi-square Test.20b, and miR-18a were observed in the L-NPC group.
They are clustered together and all from miR-17-92 cluster
and its paralogues. Of them, miR-93 gained our attention
because it shows an oncogenic potential but it has been
unclear whether miR-93 could regulate TGFBR2 in can-
cers, and no studies reported its roles and target genes in
NPC. We applied qRT-PCR to confirm that miR-93 was
highly expressed in NPC samples (Figure 2B) and 5 NPC
cell lines (Additional file 2: Figure S4), and also observe
that TGFβR2 expression was inversely correlated with
miR-93 expression (R2 = 0.3995) (Figure 2C, Additional file
2: Figure S3), suggesting that miR-93 may regulate TGFβR2.
To determine whether TGFβR2 was a direct target of
miR-93, we performed a bioinformatic analysis using
RNAhybrid and TargetScan. It showed a complementaryion from normal epithelium to NPC
P value
S/N A/N C/N A/C S/C
0.614# 0.005# <0.001# 0.401# <0.001#
Figure 2 miR-93 directly suppresses TGFβR2 in NPC. (A) miRNA expression profiling analysis in three subgroups of clinical samples including 8
NP with high TGFβR2 expression (H-NP, a blue bar on top), 7 NPC with high TGFβR2 expression (H-NPC, a brown bar on top) and 7 NPC with low
TGFβR2 expression (L-NPC, a red bar on top). (B) qRT-PCR validation of miR-93 expression in 22 clinical tissue samples. Values represent mean ± SD,
n = 3. **P < 0.01. ***P < 0.001. (C) Correlation analysis between TGFβR2 and miR-93 in 22 clinical tissue samples. (D) RNAhybrid prediction of the binding
sites of miR-93 in the 3′ UTR of TGFβR2. Luciferase activities of dual luciferase reporter carrying a wild-type or mutant of TGFβR2 3′ UTR in the indicated
cells in triplicate. Values represent mean ± SD. *P < 0.05. (E, F) The detection of TGFβR2 mRNA and protein expressions by qRT-PCR and Western blot in
CNE1 and CNE2 cells transfected with miR-93 mimic and inhibitor respectively. Values represent mean ± SD, n = 3. **P < 0.01.
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TGFβR2 (Figure 2D, Additional file 2: Figure S5). Subse-
quent dual-luciferase reporter assays reveal that miR-93
significantly attenuated the luciferase activity of reporter
vector with the wt 3′UTR of TGFβR2, whereas this ef-
fect was abrogated when the 3′UTR-binding site was
mutated, supporting that this miRNAs directly regulated
TGFβR2 by binding to its 3′UTR (Figure 2D).
According to the relatively high TGFβR2 expression in
CNE1 cells and low in CNE2 cells (Additional file 2:
Figure S2) as well as relatively low miR-93 expression in
CNE1 cells and high in CNE2 cells (Additional file 2:
Figure S4), we transfected CNE1 and CNE2 cells withmiR-93 mimic and inhibitor, respectively. Both TGFβR2
mRNA and protein expression levels were observed to de-
cline in CNE1 cells and increase in CNE2 cells (Figure 2E, F)
accordingly. These data further support that miR-93 dir-
ectly suppresses TGFβR2 in NPC.MiR-93-mediated TGFβR2 down-regulation enhances NPC
aggressiveness
To explore the roles of miR-93-mediated TGFβR2
down-regulation in NPC aggressiveness, CNE1 and
CNE2 cells were used in both gain- and loss-of-function
analyses.
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sible for NPC cell growth and proliferation after regulat-
ing TGFβR2 expression (Figure 2E, F). Colony formation
assays showed that miR-93 mimic increased cell growth
in CNE1 cells, whereas its inhibitor reduced cell growth
in CNE2 cells (Figure 3A, B). Consistent results ap-
peared in MTT assays (Additional file 2: Figure S6A, B).
Flow cytometry analysis displayed that CNE1 cells trans-
fected with miR-93 mimic exhibited a significantly re-
duced cell proportion in G1 phase and an increased cell
proportion in S-phase. CNE2 cells transfected with miR-
93 inhibitor showed opposite alterations (Figure 3A, B,
Additional file 2: Figure S7).
We next studied whether miR-93 was also involved in
NPC cell invasion and migration after regulating TGFβR2
expression (Figure 2E, F). Cell migration/invasion assays
displayed that miR-93 mimic enhanced cell migration
and invasion in CNE1 cells (Figure 3A, Additional file 2:
Figure S8A), whereas miR-93 inhibitor restricted cell migra-
tion and invasion (Figure 3B, Additional file 2: Figure S8B)
in CNE2 cells.Figure 3 MiR-93-mediated TGFβR2 down-regulation promotes NPC ag
formation, cell cycle distribution, and Transwell migration assays in CNE1 ce
presented as mean ± SEM. (Original magnification 200×). (B) Representative
migration assays in CNE2 cells treated with miR-93 inhibitor. Data are prese
reproducible in three independent experiments. *P < 0.05, **P < 0.01, ***P <Impressively, further investigation showed that the
knockdown of TGFβR2 by siRNA (Additional file 1:
Table S4, Additional file 2: Figure S10A) enabled a
reduced TGFβR2 protein expression (Additional file 2:
Figure S10B) along with enhanced proliferation and mi-
gration in CNE1 cells (Figure 3C). This phenocopied the
effect of miR-93 and supported the major involvement
of TGFβR2.
To support in vitro results, we also conducted in vivo
experiments. The CNE1 cell line stably-expressing miR-93
(CNE1-miR-93) was firstly generated using EGFP-Lenti-
miR-93-vector (Additional file 2: Figure S11). Subse-
quently, we established xenograft mouse models subcuta-
neously injected with CNE1-miR-93 cells and miR-control
cells. We observed that CNE1-miR-93 cells produced big-
ger tumor volumes in mouse models (Figure 4A). Immu-
nohistochemistry (IHC) on tissue sections derived from
tumors showed that TGFβR2 protein expression was
reduced in the tumor induced by CNE1-miR-93 cells
(Figure 4B). Additionally, we set up NPC metastasis
mouse models by transplanting CNE1-miR-93 cells andgressiveness in vitro. (A, C) Representative results of colony
lls treated with miR-93 mimic and siRNA-TGFβR2 respectively. Data are
results of colony formation, cell cycle distribution, and Transwell
nted as mean ± SEM. (Original magnification 200×). All results are
0.001.
Figure 4 MiR-93-mediated TGFβR2 down-regulation facilitates NPC aggressiveness in vivo. (A) Tumor cells were subcutaneously injected
into nude mice (5 mice each group). Pictures of subcutaneous tumor tissues were showed in whole nude mice injected with CNE1-miR-93 cells
(red arrow) and CNE1-miR-C cells (yellow arrow). Tumor volumes were determined by measuring the major (a) and minor (b) diameters at the
indicated time points, calculated according to the formula = 0.5 × a × b2, and plotted as the mean ± SD. ***P < 0.001. (B) TGFβR2 protein expression
was examined using IHC in tumor tissues derived from the indicated mouse group (400×). (C) The representative GFP images of mouse models trans-
planted by CNE1-miR-93 cells (upper) and CNE1-miR-C cells (lower). The whole mouse body and resected organs were showed separately. The primary
and metastatic tumors were displayed with green fluorescence under whole body imaging system. In the GFP images of resected organs, the lungs
(red arrow), liver (yellow arrow), kidneys, and lymph nodes (white arrow) were placed from the upper to bottom respectively and the spleen is at the
right side. (D) The differences of pulmonary or lymphatic metastasis between two groups (n = 8 per group; Fisher’s exact test. *P < 0.05) and the num-
ber of lymph node metastasis of mice (mean ± SD, 5.375 ± 1.349 and 0.625 ± 0.4799 in miR-93 cells and control cells respectively, P = 0.0046).
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The whole body fluorescent imaging system displayed a
high metastasis status in a representative CNE1-miR-93
cell-injected mouse. The pulmonary or lymphatic metas-
tasis incidence was obviously higher in CNE1-miR-93 cell-
injected mice than in control mice (Figure 4C, D). Not-
ably, miR-93 cells resulted in significantly more lymph
node metastases (5.375 ± 1.349) than that of control cells
in mouse models (0.625 ± 0.4799) (P = 0.0046) (Figure 4D).
Collectively, these in vitro and in vivo data suggest that
miR-93-mediated TGFβR2 down-regulation promote NPCaggressiveness through enhancing NPC cell proliferation,
invasion and metastasis.
MiR-93 regulates a Smad-dependent and a
Smad-independent TGF-β signaling by suppressing
TGFβR2
TGFβR2 is an important component in TGF-β signaling.
Its loss or reduced expression may impair TGF-β signal-
ing. To examine if miR-93 is involved in the abrogation
of this signaling pathway, the phosphorylation of
Smad2/3, a key protein in this pathway, was detected in
Figure 5 Regulation of Smad-dependent TGF-β signaling, PI3K/Akt signaling, cell cycle progression and EMT by miR-93-mediated
TGFβR2 inactivation in NPC cells. (A) Western blotting analyses of Smad2/3 and its phosphorylation as well as PI3K and p-Akt in the indicated
cell groups. (B) Western blotting analyses of C-myc, E2F1, cyclin D1, CDK4 and p21 in the indicated cell groups. (C) Western blotting analyses of
Snail, E-cadherin, and Vimentin in the indicated cell groups. (D) The morphological observations of the indicated cell lines. CNE1 cells were
transfected with miR-93 mimic/siRNA-TGFβR2 and miRNA/siRNA control for 96 hours and analyzed under phase contrast microscopy (400×).
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and inhibitor respectively. As shown in Figure 5A and
Additional file 2: Figure S12A, the introduction of miR-93
did attenuate p-Smad2/3 expression, whereas silencing of
miR-93 increased p-Smad2/3 expression. Notably, the re-
duction of p-Smad2/3 expression was also observed in
CNE1 treated with siRNA-TGFβR2, similar to the effect
of miR-93 (Figure 5A). These data indicate that miR-93 at-
tenuates Smad-dependent TGF-β signal though suppress-
ing TGFβR2.
PI3K/Akt signaling pathway is a central regulator in
cancer cell proliferation, metastasis and EMT process.
Multiple studies have suggested the existence of direct
[52,53] or indirect [54-57] crosstalk between TGF-β sig-
naling and PI3K/Akt signaling, so we wonder whether
PI3K/Akt pathway is also involved in NPC aggressive-
ness in the presence of miR-93-mediated TGFβR2 in-
activation. To test this, we examined the expressions of
PI3K and p-Akt, after treating CNE1 and CNE2 cells
with miR-93 mimic or siRNA-TGFβR2 and miR-93 in-
hibitor respectively. Our results showed that miR-93mimic could elevate the expressions of PI3K and p-Akt
in CNE1 cells, whereas its inhibitor could reduce the ex-
pressions of PI3K and p-Akt in CNE2. As expected,
siRNA-TGFβR2 displayed a consentaneous phenocopy
with the effect of miR-93 mimic in CNE1 cells (Figure 5A,
Additional file 2: Figure S12A), suggesting the down-
regulated TGFβR2 could enhance PI3K/Akt pathway.
Next, we performed western blotting to check the ex-
pression alterations of some important proteins related to
cell proliferation, cell cycle and EMT process in CNE1
cells transfected with miR-93 mimic or siRNA-TGFβR2
and in CNE2 cells transfected with miR-93 inhibitor. Not-
ably, miR-93 mimic or siRNA-TGFβR2 could increase the
expression of c-myc, E2F1 and cyclin D1, and reduce p21
expression in CNE1 cells. Conversely, miR-93 inhibitor
could reduce the expression of c-myc, E2F1 and cyclin
D1, and increase p21 expression in CNE2 cells (Figure 5B,
Additional file 2: Figure S12B).
EMT has been regarded as an important mechanism
that facilitates cancer cell migration and leads to metas-
tasis, so we also tested whether miR-93 is involved in
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Figure 5C and Additional file 2: Figure S12C, both miR-93
mimic and siRNA-TGFβR2 resulted in the highly expressed
transcriptional factor Snail, reduced E-cadherin expression
and increased Vimentin expression in CNE1 cells, whereas
miR-93 inhibitor caused opposite alterations in CNE2 cells.
Morphological observation showed that miR-93 mimic or
siRNA-treated NPC cells lost their cell-to-cell adhesions
and acquired spindle-like morphology, whereas the con-
trol cells remained cobblestone-like epithelial appearance
(Figure 5D).
Collectively, these data suggest that miR-93-mediated
TGFβR2 down-regulation could result in the attenuation
of Smad-dependent TGF-β signaling and the activation
of PI3K/Akt pathway in NPC aggressiveness. Some cell
cycle, cell proliferation and EMT-associated genes were
altered in NPC cells in the presence of miR-93-mediated
TGFβR2 down-regulation.
TGF-β1 is one of the most important TGF-β signaling
components, so we also detected its expression alteration
in the presence of miR-93-mediated TGFβR2 down-
regulation. Notably, miR-93 or siRNA-TGFβR2 could give
rise to an increased TGF-β1 expression in CNE1 cells and
an increased TGF-β1 secretion in the culture supernatants
of CNE1 cells, whereas miR-93 inhibitor enabled inverse
alterations in CNE2 cells (Additional file 2: Figure S9),
suggesting a possible feedback loop from miR-93-mediated
TGFβR2 to TGF-β1 existed in NPC cells.Figure 6 MiR-93 and TGFβR2 were clinically associated with NPC agg
additional set of primary NPC samples. As showed in the plot diagrams, th
and clinical staging. Values represent mean ± SD, *p < 0.05 (B) qRT-PCR a
of TGFβR2 expression with T and N classifications and clinical staging in
**P < 0.01, ***P < 0.001.MiR-93 and TGFβR2 were clinically associated with NPC
aggressiveness
To further support our finding, we finally investigated
the clinical relevance of miR-93 and TGFβR2 in an add-
itional set of clinical samples. The correlations of clinical
TNM classification with the expression levels of miR-93
and TGFβR2 were analyzed (M classification was not an-
alyzed due to few patients with distant metastasis). We
observed that the expressions of miR-93 positively corre-
lated with T/N classification and clinical stage respect-
ively (Figure 6A) and TGFβR2 expression was negatively
correlated with T/N classification and clinical stage re-
spectively (Figure 6B), supporting that miR-93-mediated
TGFβR2 down-regulation was closely linked to NPC
aggressiveness.
Discussion
The role of TGFBR2 in oncogenesis has been investigated
in several cancer types. Loss of TGFβR2 was reported in
nasopharyngeal carcinoma (NPC) in our previous study
[40]. The downregulation of TGFBR2 expression in cancer
cells can be caused by multiple mechanisms, including
hypermethylation of the TGFBR2 promoter and, as we
show here, through miRNA regulation. MiR-17-92 and its
paralogues are the best-known miRNA clusters. Their
members have pivotal roles in normal development, and
dysregulation of their expressions leads to a wide array of
diseases and cancers. In the beginning of our study, weressiveness. (A) The detection of miR-93 expression by qRT-PCR in an
e miR-93 expression was positively correlated with T, N classification
nalysis of TGFβR2 mRNA expression showed a negative correlation
scatter plot diagrams. Values represent mean ± SD, *P < 0.05,
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using a global miRNA expression profiling analysis of clin-
ical samples (data not shown but available in GEO data-
base. Accession Number is GSE42945), similar to other
studies [58,59]. Alternatively, based on this miRNA expres-
sion profiling data, we next re-classified clinical samples
into high and low TGFβR2 expression NPC subgroups
and normal control group, and interestingly discovered a
cluster set of TGFβR2-associated miRNAs (miR-93, miR-
20a, miR-20b and miR-18a), which all belong to miR-17-
92 cluster and its paralogues.
To our knowledge, few lines of evidence support that
miR-17-92 cluster and its paralogues may contribute to
the regulation of TGFβR2 function in cancer. MiR-17-5p
and miR-20a could repress TGFβR2 in HCT116 p53-
null human colon carcinoma cells [60]. Stefano Volinia
et al. also experimentally confirmed that TGFBR2 is a
target of miR-20a by luciferase reporter assay [61]. Re-
cently, some studies have identified some miR-93 targets
that mediate oncogenesis and cancer progression in sev-
eral different cancer types [30,32,33,35,62]. Our study
finds that TGFBR2 is a major miR-93 target that medi-
ates the oncogenic function in NPC.
In the current study, we conducted an integrated ap-
proach comprising in vitro, in vivo and clinical analyses
to explore the roles of this miR-93-mediated TGFβR2
down-regulation. Multiple sets of clinical data were used
to raise our hypotheses and support our research con-
clusions. Our results demonstrate that miR-93-mediated
TGFβR2 down-regulation contributes to NPC aggres-
siveness including cell growth and proliferation as well
as cancer metastasis and invasion. A recent prognostic
study reported a correlation of miR-93 expression level
with NPC prognosis [63]. This study didn’t further in-
vestigate the associated molecular mechanism, but it
supported our findings. Combining this research data
with ours, we conclude that up-regulated miR-93 and
down-regulated TGFβR2 may be a dominant functional
combination in clinical NPC aggressiveness; miR-93 pro-
motes NPC aggressiveness through down-regulating
TGFβR2.
It is best known that TGF-β and PI3K/AKT signal
transductions are two pivotal pathways that control cell
function. Importantly, PI3K/Akt pathway could be dir-
ectly or indirectly regulated by TGF-β [52-57,64]. In the
present study, we provided further evidence that miR-
93-mediated TGFβR2 inactivation not only pulled down
the TGF-β signaling but also activated PI3K/Akt path-
way in NPC aggressiveness. Subsequently, we observed
the high expression of two important transcriptional fac-
tors, c-myc and snail that are closely associated with
cancer cell proliferation, migration and EMT process.
The obvious expression alterations of some important
genes related to cell proliferation, cell cycle and EMTconcurrently appeared in NPC cells in the presence of
miR-93-mediated TGFβR2 inactivation. In Particular, the
knockdown of TGFβR2 by siRNA displays a consentane-
ous phenocopy with the effect of miR-93. These date sup-
port a major involvement of miR-93-medited TGFβR2
inactivation that drives down the TGF-β signaling and ac-
tivates PI3K/Akt pathway in NPC aggressiveness.
In addition, a relatively high intracellular expression
and secretion of TGF-β1 were observed upon miR-93-
mediated TGFβR2 down-regulation, which was consist-
ent with a report by Munoz [65] who believed that it
was possibly due to the attenuated TGF-β signaling
pathway. This hints its undefined effects on NPC aggres-
siveness, which deserves further investigations.
Conclusions
Our study identifies a miR-93-mediated TGFβR2 down-
regulation in NPC and its link to NPC aggressiveness.
We also discovered an involvement of Smad-dependent
TGF-β signaling attenuation and PI3K/Akt activation.
This study presents some useful insights into molecular
mechanisms underlying NPC aggressiveness and pro-
vides potential implications for clinical application.
Materials and methods
Clinical samples and cell lines
14 fresh NPC specimens and 8 fresh NP were used for
miRNA expression profiling analysis, microarray valid-
ation, and correlation analysis. A second cohort of NPC
containing 55 fresh-frozen NPC specimens with TNM
classification was used for clinical evaluations. 300 paraffin
embedded sections from NPC, atypical hyperplasia (AH),
normal squamous epithelium (NS) and normal nasophar-
ynx epithelium (NN) were employed for histological ex-
aminations. All tissue samples were collected from the
patients that were confirmed by pathological examination
and not pretreated with radiotherapy or chemotherapy in
Zhongshan Hospital, Zhongshan City, Guangdong, China.
Staging was performed according to the 1992 Fuzhou
NPC staging system of China [66]. Clinical tissue studies
for research purposes have received patient’s informed
consents and the approval from the Ethics Committee of
Southern Medical University, China. Immortalized pri-
mary nasopharyngeal epithelial cell line (NP69) and 4
NPC cell lines (CNE1, CNE2, 5-8 F, 6-10B) were obtained
from Cancer research institute of Southern medical uni-
versity, Guangzhou, China.
MiRNA expression profiling analysis
The miRNA microarrays (CCDTM-miRNA 850-V4p1.4)
were provided by Infectious Disease and Immunogenetics
Section, DTM, Clinical Center of the National Institutes
of Health, USA. Briefly, 7-10 μg of total RNA from each
sample was used for hybridization on miRNA microarray
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power labeling kit (Exiqon) according to manufacturer's
instruction. The microarray was hybridized at 25°C for
18 hrs, washed in washing buffers at 37°C for 1 min, and
scanned on a LuxScan 10 k microarray scanner (Lux-
ScanTM10K-A, CapitalBio Corporation). Resulting data
were quantified, normalized and analyzed by the Lux-
ScanTM 3.0 software (CapitalBio Corporation, China),
and then uploaded to the mAdb database (http://nciarray.
nci.nih.gov).
The raw data were filtered according to standard pro-
cedure to exclude spots with minimum intensity and size,
normalized using Lowess Smoother, and retrieved by the
BRBArray-Tool (http://linus.nci.nih.gov/BRB-ArrayTools.
html). Clustering and visualization of expression profiles
were preformed with Cluster and Treeview [67].
Extraction of total RNA and quantitative RT-PCR
Total RNAs were extracted from tissues and cell lines with
TRIzol (Invitrogen) according to the user manual. For
mRNA expression analysis, 1 μg of total RNA was used
for RT using PrimerScriptTM RT Kit following the manu-
facturers protocol (TaKaRa), and real-time PCR was per-
formed using SYBR® Premix Ex Taq™ Real Time PCR Kit
(TaKaRa) on an Mx3000P Stratagene. All data were nor-
malized to GAPDH expression and further normalized to
the negative control unless otherwise indicated. Primer se-
quences for TGFβR2 (forward: 5′-AAGATGACCGCTC
TGACATCA-3′, reverse: 5′-CTTATAGACCTCAGCGA
C-3′) and GAPDH (forward: 5′-CCATGAGAAGTATGA
CAAC AGCC-3′, reverse: 5′-GGGTGCTAAGCAG TTG
GTG-3′) were acquired from Primer-bank (http://pga.
mgh.harvard.edu/primerbank/). For miRNA expression
analysis, mature miRNAs were reverse-transcribed for
subsequent real-time PCR using All-in-One™ miRNA
qRT-PCR Detection Kit following the manufacturer’s
protocol (GeneCopoeia). All data were normalized to U6
expression. The fold changes were calculated by relative
quantification (2−ΔΔCt). QRT-PCR was conducted for each
sample in triplicate.
Cell culture and transfections
NPC cell lines were cultured in RPMI-1640 (HyClone)
with 10% calf serum (Gibco). For transfection, the
medium was changed to the Dulbecco’s modified Eagle’s
medium, DMEM (Gibco) with 10% fetal bovine serum
(Gibco). Cells were maintained in a humidified atmosphere
of 5% CO2 at 37°C and seeded on six-well plates (NEST,
China) 24 hours prior to transfection. SiRNA-TGFβR2-
1515 (Additional file 1: Table S4, Additional file 2: Figure
S10) (GenePharma), miRNA-93 mimic and inhibitor (Gen-
ePharma) were transfected into cells respectively at a final
concentration of 50 nmol/L using Lipofectamine™ 2000
(Invitrogen) in serum-free conditions. After 5 hours, themedium was changed to fresh DMEM (Gibco) with 10%
fetal bovine serum.
Dual luciferase assay
To generate the luciferase reporter constructs psiCHECK2-
TGFβR2-3′UTR(wt) and psiCHECK2-TGFβR2-3′UTR(mut),
complimentary oligonucleotides containing the wild type
3′UTR of TGFβR2 (3′UTR of TGFβR2 was divided into 2
segments (0.15 KB-0.6 KB and 1.5 KB-2.5 KB) and
TGFβR2 3′UTR with point mutations in miR-93 target
sites, respectively, were annealed. Oligonucleotide se-
quences were as follows: TGFβR2-wt 0.15 kb-0.6 kb:
forward5′-ATCGCTCGAGCAGCAGGGAGTGGGTGA
CAT-3′, reverse: 5′-AT CGCGGCCGCTGGCTGTGAG
ACATGGAGCC-3′. 1.5 kb-2.5 kb: forward: 5′-ATCGTC




AA CTATT-3′. Annealed oligonucleotides were ligated
into the XhoI/NotI site of psi-CHECK2 renilla/firefly
dual-luciferase expression vector. Mutant reporter plas-
mids were obtained from this plasmid using a KOD-Plus-
Mutagenesis Kit (SMK-101, Toyobo Co., Ltd. Life Science
Department, Osaka Japan). All inserts were verified by
DNA sequencing. Luciferase assays were conducted using
293 T cells plated in a 24-well plate (NEST). Transfections
were performed using Lipofectamine™ 2000 (Invitrogen)
in OptiMEM serum free media (Gibco).
Cell migration and invasion assays
For migration assays, 2 × 105 NPC cells transfected with
miRNA-93 mimic or siRNA- TGFβR2 and miRNA-93
inhibitor respectively for 48 hours were re-suspended in
serum-free media and placed in inserts containing 8 μm
pores (Corning) without extracellular matrix coating (BD
Biosciences, San Jose, CA, US). DMEM containing 10%
FBS was added to the bottom chamber. After 18 hours
and 24 hours of incubation, the cells on the lower surface
of the filter were fixed and stained followed by micro-
scopic examination. The number of cells in five random
optical fields (100× magnifications) from triplicate filters
was averaged. For in vitro invasion assays, the inserts of
the chambers to which the cells were seeded were coated
with Matrigel (BD Biosciences).
Cell proliferation, colony formation and cell cycle
analyses
Cell proliferation was analyzed using MTT assay (Sigma,
St. Louis, USA). Briefly, CNE-1 cells (5 × 103) and CNE-2
cells (3 × 103) were plated onto 96-well plates (NEST) re-
spectively in 100 μL of growth medium and allowed to ad-
here overnight. The cells were then transfected with
50 nm of miR-93 mimic or siRNA and inhibitor
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the culture medium was removed and replaced with cul-
ture medium containing 10 μL of sterile MTT dye (5 mg/
mL). After incubation at 37°C for 4 hours, the MTT solu-
tion was removed, and 150 μL of dimethyl sulfoxide
(DMSO) was added to dissolve the formazan crystals.
Spectrometric absorbance at 490 nm was measured by
BioTek ELx800 microplate photometer (BioTek ELx800,
SN211805, US).
Colony Formation Assays were performed. CNE-1 and
CNE2 cells were transfected respectively with miR-93
mimic or SiRNA-TGFβR2 and miR-93 inhibitor and for
24 h and were pated in 6-well plates at 2×102 for
2 weeks. The plates were then washed twice with PBS,
fixed with methanol-acetic acid (3:1 V/V), and stained
with 0.5% cristal violet. The number of colonies was
counted under the microscope.
For cell cycle analysis, CNE1 cells transfected with
miR-93 mimic or siRNA-TGFβR2 and CNE2 cells trans-
fected with miR-93 inhibitor were fixed in 70% ice-cold
ethanol for 48 hours at 4°C, stained by incubation with
PBS containing 10 μg/mL propidium iodide and 0.5 mg/mL
RNase A for 15 min at 37°C, and analyzed for the DNA
content of labeled cells by FACS Caliber Cytometry (BD
Bioscience). Each experiment was done in triplicate.Lentiviral production and transduction
Lentivirus (GV209, H1-MCS-CMV-EGFP) particles
carrying hsa-pri-miR-93 precursor and its control were
purchased from GeneChem, Shanghai, China [68]
(Additional file 2: Figure S11A, B). The lentiviral transduc-
tion of CNE1 cells was carried out according to the manu-
factures’ protocol. The resulting cells were seeded onto
96-well plates and cultured for 3 weeks to produce a
stable miR-93-overexpressing CNE1 cells and CNE1 con-
trol cells (Additional file 2: Figure S11C). The high expres-
sion of miR-93 was validated by quantitative RT-PCR
(Additional file 2: Figure S11D).Tumor xenografts in nude mice
The experimental protocol was approved by the Animal
Care and Use Committee of Southern Medical University.
All mice of 4-5 weeks old and 18-20 g in weight were pro-
vided by the Central Animal Facility of Southern Medical
University.
To evaluate tumor growth in mouse models, 200 μL of
Cell suspension from 1 × 107 CNE1 expressing GFP/miR-
93 and CNE1 cells expressing vector control were sub-
cutaneously injected into the left and right sides of the
back of each mouse respectively. The tumor sizes were
measured periodically and calculated using the formula =
0.5 × a × b2 (a and b were the long and short diameters of
the tumors respectively). After mice were sacrificed in3 weeks, tumors were collected from mice for IHC detec-
tion of TGFβR2 expression.
An imageable technique in mouse models has been
developed in our laboratory before [69]. To evaluate tumor
metastasis in mouse models, we firstly made a small cut
on the abdominal region of each mouse, carefully pushed
its liver out of abdominal cavity, injected 50 μL of CNE1
cells (5×106) expressing GFP/miR-93 or an equal number
of control cells under the liver envelope of each mouse (8
mice for each group), and then softly pushed its liver back
after cleaning and lightly pressing the pinhole with alcohol
cotton balls for two minutes. All mice were sacrificed in
3 weeks. Their whole bodies and resected internal organs
(on culture plates) were subjected to fluorescent image de-
tection under LT-9MACIMSYSPLUS whole body imaging
system (Encinitas, CA, USA).
Immunohistochemical examination
Paraffin-fixed NPC sections and nude mice tumor sec-
tions were immunostained for TGFβR2 using the Ultra-
Sensitive S-P IHC Kit (Maixin-Bio, Fujian, China) and
primary antibody against TGFβR2 (1:100 dilution, Abcam),
and then colorated with DAB Kit (Maixin-Bio, China).
The immunohistochemically stained tissue sections were
reviewed and scored by two pathologists independently,
blinded to the clinical parameters. Staining intensity was
scored as previously described [70]. The extent of the
staining, defined as the percentage of positive staining
areas of tumor cells or normal nasopharyngeal epithelial
cells in relation to the whole tissue area, was scored on a
scale of 0 to 4 as the following: 0, <10%; 1, 10–25%; 2, 26–
50%; 3, 50–75%; and 4, >76%. The sum of the staining-
intensity and staining-extent scores was used as the final
staining score for TGFβR2 (0–7). For statistical analysis, a
final staining scores of 0-5 and 6-7 were respectively con-
sidered to be low and high TGFβR2 expression.
Western blot analysis
Cell lysate was prepared using RIPA buffer with protease
inhibitors and quantified using the BCA protein assay
(BioTek, China). Protein (20 μg) was loaded onto a 10%
SDS-PAGE gel that was then transferred onto PVDF
membrane and incubated with anti-TGFβR2 (Bioworld
Technology, MN.US), anti-TGF-β1 (Cell Signaling Tech-
nology), anti-PI3K (Cell Signaling Technology), anti-p-Akt
(p-Ser473, Abzoom), anti-c-myc (Santa Cruz), anti-E2F1
(Santa Cruz), anti-CCND1 (Santa Cruz), anti-p21 (Santa
Cruz), anti-E-cadherin (Bioworld Technology, MN.US),
anti-Vimentin (Bioworld Technology, MN.US), and anti-
Snail (Bioworld Technology, MN.US) at 4°C overnight in
blocker (3% non-fat dry milk/BSA in TTBS) followed by
incubation with HRP-conjugated secondary anti mouse
(ZSGB-Bio, China). Protein was normalized with GAPDH
(Abmart).
Lyu et al. Molecular Cancer 2014, 13:51 Page 12 of 14
http://www.molecular-cancer.com/content/13/1/51Enzyme-linked immunosorbent assay (ELISA)
CNE1 cells transfected with miR-93 mimic or siRNA-
TGFβR2 and CNE2 cells transfected with miR-93 inhibi-
tor were incubated in 8 ml RPMI-1640 (HyClone) with
10% calf serum (Gibco) for 48 hours. When cells were
harvested, the media were placed in the ELISA plates
(KeyGen Biotech Co. Ltd, China). ELISA of TGF-β1 was
performed following the routine manual.
Statistical analysis
All statistical analyses were performed by the SPSS 13.0
statistical software package (SPSS Inc. Chicago, IL, USA).
The Kruskal Wallis test and χ2 test were used to compare
gene expression levels of different histological types. The
χ2 test was used to analyze the relationship between the
levels of TGFβR2 expression and clinicopathologic charac-
teristics. Survival curves were plotted using the Kaplan-
Meier method and compared using the log-rank test. The
significances of various variables in survival were analyzed
using the multivariate Cox proportional hazards model.
Two-tailed Student’s t test was used to determine the dif-
ference between two groups, while ANOVA was used for
the comparison of more than two groups. Fisher’s exact
test was employed when sample sizes were relatively
small. The differences were considered to be statistically
significant when p-value <0.05. All data were presented as
mean ± SD or SEM unless otherwise noted.Additional files
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